I-Mab Founder Retakes Reins in Latest Shakeup Ahead of Commercialization Phase
Drug maker announces latest senior appointments as investors anticipate regulatory approval for some of its products as early as 2023 Key takeaways Four-year company veteran and CEO Joan Shen to…
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Innogen Pharma jostles for a slice of the weight-loss market
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
